Addex Therapeutics

Company snapshot

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 40 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Addex Therapeutics. Not investment advice.

• Peer + 0 momentum

  H. Lundbeck A/S

  TA overlap score 33.4

• Peer + 0 momentum

  SUPERNUS PHARMACEUTICALS

  TA overlap score 31

Recent activity

Latest pipeline, patent, and corporate events for Addex Therapeutics.

1. Jun 8, 2026 Clinical update

   ADX10059 — Phase 2

2. Jun 5, 2026 Clinical update

   Dipraglurant — Phase 3

3. Jun 5, 2026 Clinical update

   ADX48621 — Phase 2

4. Jun 5, 2026 Clinical update

   ADX10059 — Phase 2

5. May 23, 2026 Clinical update

   Dipraglurant — Phase 2

View all clinical trial activity →

• What is Addex Therapeutics?

  Addex Therapeutics is a pharma organization headquartered in GENEVA, V8, CH. It trades on NYSE under ticker ADXN. Primary therapeutic focus areas include Gastroesophageal Reflux, Migraine, Parkinson's Disease, Blepharospasm, Parkinson Disease. NovaPharmaNews links 6 clinical prog

• Is Addex Therapeutics publicly traded?

  Yes. Addex Therapeutics is listed with ticker ADXN on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Addex Therapeutics develop or market?

  We link 3 drug profile(s) where Addex Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/addex-therapeutics#company-drugs.

• What are the latest developments for Addex Therapeutics?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Addex Therapeutics focus on?

  Addex Therapeutics focuses on Gastroesophageal Reflux, Migraine, Parkinson's Disease based on our analysis of their pipeline programs and drug development activities.